Clinical Trials
19 trialsNCT07593092 2026-05-18
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Not yet recruiting
NCT07487168 2026-05-15
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Not yet recruiting
NCT06233331 2026-05-08
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
Emory University
Phase 1 Not yet recruiting
NCT07542704 2026-04-21
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
Phase 1 Not yet recruiting
NCT07532148 2026-04-15
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Chong Kun Dang Pharmaceutical
Phase 1 Not yet recruiting
NCT07383506 2026-03-27
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1 Not yet recruiting
NCT07489287 2026-03-27
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Phase 1 Not yet recruiting
NCT07462468 2026-03-13
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
WestVac Biopharma Co., Ltd.
Phase 1 Not yet recruiting
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07088588 2025-07-28
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1 Not yet recruiting
NCT06846424 2025-02-26
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 1 Not yet recruiting
NCT06760676 2025-01-07
A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy
Anhui Provincial Hospital
Phase 1 Not yet recruiting
NCT06754761 2025-01-01
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
AstraZeneca
Phase 1 Not yet recruiting
NCT06748872 2024-12-27
EPITOME-1015-I
Medigene AG
Phase 1 Not yet recruiting
NCT06652529 2024-11-07
AROG4-01-01
Aromics Therapeutics
Phase 1 Not yet recruiting
NCT06614751 2024-09-27
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Danatlas Pharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT06415500 2024-05-16
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites
Anhui Provincial Hospital
Phase 1 Not yet recruiting
NCT06383507 2024-04-25
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
Phase 1 Not yet recruiting
NCT06358053 2024-04-10
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Not yet recruiting